Last10K.com

Epizyme, Inc. (EPZM) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

EPZM Quarterly Reports

Epizyme, Inc.

CIK: 1571498 Ticker: EPZM

Exhibit 99.1

Epizyme Reports Business Progress and First Quarter 2020 Financial Results

TAZVERIK Successfully Launched for First Approved Indication; PDUFA Date of June 18,

2020 for sNDA for Follicular Lymphoma Indication

Business Continuity Plans in Place in Response to COVID-19

Conference Call to be Held Today, May 4 at 9:00 a.m. ET

CAMBRIDGE, Mass., May 4, 2020Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results.

“The first quarter of 2020 was significant for Epizyme, marked by the FDA approval of TAZVERIK in eligible patients with epithelioid sarcoma and our transition to a commercial-stage company,” said Robert Bazemore, president and chief executive officer of Epizyme. “Despite the global challenges as a result of the COVID-19 pandemic, and the continued uncertainties in the recovery process, we know that patients with cancer still need better treatments, and we remain committed to advancing innovative medicines on their behalf. In addition to continuing our commercialization of TAZVERIK for epithelioid sarcoma, a critical activity for our organization, we are preparing to launch in follicular lymphoma, should TAZVERIK be approved for that indication. We believe strongly in TAZVERIK’s potential to make a meaningful impact in the lives of patients.”

COVID-19 Response

In response to the ongoing COVID-19 pandemic, Epizyme has activated business continuity plans to allow for the continued advancement of TAZVERIK commercialization, tazemetostat clinical development expansion and the company’s early pipeline, which are designed to minimize disruptions and protect the safety of its employees. Epizyme continues to assess the situation and any potential impact it may have on its operations, financial guidance and plans, and will provide updates accordingly. Measures implemented to date that address challenges resulting from the global pandemic include:

 

   

Employee Safety and Remote Operations: A remote operating model for in-house and field-based employees was implemented in early March, with the exception of a small number of employees to continue critical lab and information technology operations.

 

   

Patient Access to TAZVERIK: Epizyme is leveraging a specialty pharmacy and specialty distributors to support seamless patient access, and currently expects to be able to provide an uninterrupted supply of TAZVERIK for commercial use and the company’s ongoing clinical trials.

 

   

U.S. Commercialization: Epizyme is leveraging virtual personal and non-personal approaches to engage and reach customers.


The following information was filed by Epizyme, Inc. (EPZM) on Monday, May 4, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Epizyme, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Epizyme, Inc..

Continue

Assess how Epizyme, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Epizyme, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Expense
Shares
Income
Other
Inside Epizyme, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Operations And Comprehensive Loss
Condensed Consolidated Statements Of Stockholders' Equity
Condensed Consolidated Statements Of Stockholders' Equity (Parenthetical)
Cash
Cash (Tables)
Cash - Additional Information (Detail)
Cash - Summary Of Reconciliation Of Cash, Cash Equivalents, And Restricted Cash (Detail)
Collaborations
Collaborations - Additional Information (Detail)
Commitments And Contingencies
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Summary Of Company's Financial Assets Recognized At Fair Value (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
Inventory
Inventory (Tables)
Inventory - Summary Of Inventories (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Future Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)
Leases - Summary Of Lease Costs And Company's Operating Leases (Detail)
Long Term Debt (Tables)
Long-Term Debt
Long-Term Debt - Additional Information (Detail)
Long-Term Debt - Schedule Of Minimum Aggregate Future Loan Payments (Detail)
Loss Per Share
Loss Per Share (Tables)
Loss Per Share - Common Stock Equivalents From Calculation Of Diluted Loss Per Share Attributable To Common Stockholders (Detail)
Loss Per Share - Schedule Of Basic And Diluted Loss Per Share (Detail)
Marketable Securities
Marketable Securities (Tables)
Marketable Securities - Additional Information (Detail)
Marketable Securities - Summary Of Available-For-Sale Securities Held (Detail)
Product Revenue Net
Product Revenue Net (Tables)
Product Revenue Net - Additional Information (Detail)
Product Revenue Net - Summary Of Product Revenue Allowance And Reserve Categories (Detail)
Sale Of Future Royalties
Sale Of Future Royalties (Tables)
Sale Of Future Royalties - Additional Information (Details)
Sale Of Future Royalties - Schedule Of Activity Of Royalty Obligation (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Assumptions Used In Applying Pricing Model (Detail)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Detail)
Stock-Based Compensation - Summary Of Performance Based Restricted Stock Units (Detail)
Stock-Based Compensation - Summary Of Service Based Restricted Stock Units (Detail)
Stock-Based Compensation - Summary Of Stock Option Activity (Detail)
Stockholders' (Deficit) Equity
Stockholders' (Deficit) Equity - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Summary Of Intangible Assets (Detail)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Schedule Of Accrued Expenses (Detail)
The Company
The Company - Additional Information (Detail)
Ticker: EPZM
CIK: 1571498
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-020616
Submitted to the SEC: Mon May 04 2020 6:59:08 AM EST
Accepted by the SEC: Mon May 04 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/epzm/0001564590-20-020616.htm